$ALNY News Leading stocks prove their mettle 11:
Post# of 144509
Posted On: 12/16/2013 10:11:15 AM
$ALNY News
Leading stocks prove their mettle 11:53 a.m. Aug. 22, 2013 - The Trading Deck
Don't fight the tape 10:27 a.m. May 28, 2013 - The Trading Deck
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Synageva director bought shares for trust 1:41 p.m. Jan. 17, 2013 - Insider Monkey
Six stocks to watch for potential up moves 11:14 a.m. Jan. 17, 2013 - The Trading Deck
S&P 500 challenges the 1,440 resistance 9:27 a.m. Sept. 13, 2012 - Michael Ashbaugh
Investing in ‘junk DNA’ 9:28 p.m. Sept. 11, 2012 - Jen Wieczner
Monsanto inks biopesticides deal with Alnylam 8:30 a.m. Aug. 28, 2012 - MarketWatch.com
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 2:35 p.m. July 16, 2012 - MarketWatch
Alnylam soars 31% on drug study 10:19 a.m. July 16, 2012 - Val Brickates Kennedy
Alnylam: Progress with genetic-disorder treatment 6:35 a.m. July 16, 2012 - MarketWatch.com
3 med stocks to get your heart pumping 12:53 p.m. April 5, 2012 - The Trading Deck
Stocks to watch Thursday: GM, Agilent, NetApp 6:51 a.m. Feb. 16, 2012 - MarketWatch
Alnylam climbs 16% on stock offer pricing 2:07 p.m. Feb. 15, 2012 - Val Brickates Kennedy
Stocks to watch Wednesday: Hartford, Aflac, Zynga 6:45 a.m. Feb. 15, 2012 - MarketWatch
Tuesday’s biggest gaining and declining stocks 5:47 p.m. Feb. 14, 2012 - Sue Chang
MGM, Monsanto among Tuesday upgrades 10:54 a.m. Sept. 13, 2011 - Tom Bemis
Vertex, Alnylam gain in drug-stock trading 12:22 p.m. Feb. 23, 2011 - Val Brickates Kennedy
Alnylam shares jump on analyst upgrade 9:55 a.m. Feb. 23, 2011 - Val Brickates Kennedy
Alnylam: Bold Moves Toward A New Class Of Medicine 6:33 p.m. Dec. 11, 2013 - Seeking Alpha
Isis Ally Alnylam - Trying To Understand Its Astounding Valuations 10:06 a.m. Dec. 10, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH 7:59 p.m. Dec. 9, 2013 - benzinga.com
Alnylam's CEO Presents at The 25th Annual Piper Jaffray Healthcare Conference (Transcript) 4:21 p.m. Dec. 4, 2013 - Seeking Alpha
Best Biotech CEO of 2013: Your Vote Counts 8:07 a.m. Dec. 4, 2013 - TheStreet.com
Alnylam Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) 2:01 p.m. Dec. 2, 2013 - Seeking Alpha
Alnylam Earns Milestone Payment - Analyst Blog 5:52 p.m. Nov. 26, 2013 - Zacks.com
Today's Stocks Driving Success For The Drugs Industry 12:04 p.m. Nov. 26, 2013 - TheStreet.com
Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran 6:02 a.m. Nov. 25, 2013 - benzinga.com
Biotech Stock Roundup: Vanda Soars, Sarepta Slumps - Analyst Blog 11:33 a.m. Nov. 20, 2013 - Zacks.com
First Week Of ALNY January 2014 Options Trading 11:55 a.m. Nov. 19, 2013 - TheStreet.com
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American Heart Association Meeting 3:54 p.m. Nov. 17, 2013 - benzinga.com
Alnylam Pharmaceuticals Larger Than S&P 500 Component Teradyne 4:39 p.m. Nov. 15, 2013 - TheStreet.com
Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial 8:26 a.m. Nov. 10, 2013 - benzinga.com
Wider-than-Expected Q3 Loss at Alnylam - Analyst Blog 10:00 a.m. Nov. 7, 2013 - Zacks.com
10-Q: ALNYLAM PHARMACEUTICALS, INC. 8:20 a.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Alnylam Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript 11:43 p.m. Nov. 6, 2013 - Seeking Alpha
3 Potential Game-Changers In The Biotech Industry 4:45 p.m. Nov. 5, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AAT 3:12 p.m. Nov. 2, 2013 - benzinga.com
Pipeline Progress at Alnylam - Analyst Blog 6:05 p.m. Oct. 30, 2013 - Zacks.com
Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR) 8:00 a.m. Today - BusinessWire
Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on Medtronic, Auxilium, Alnylam, Infinity, and Halozyme 8:00 a.m. Dec. 11, 2013 - PR Newswire
Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD) 7:00 p.m. Dec. 9, 2013 - BusinessWire
New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 7:30 p.m. Dec. 8, 2013 - BusinessWire
Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena Biopharma, Amedisys, and Aeterna Zentaris 8:00 a.m. Dec. 3, 2013 - PR Newswire
Alnylam to Webcast Presentation at Upcoming Investor Conferences 4:00 p.m. Nov. 25, 2013 - BusinessWire
Upcoming Webinars, FDA Clearances, Preclinical Data Presentations, Completed Acquisitions and Financial Results - Research Report on Teva, Boston Scientific, Alnylam, Wright Medical, and Onconova 8:00 a.m. Nov. 25, 2013 - PR Newswire
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 25, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting 4:00 p.m. Nov. 17, 2013 - BusinessWire
Healthcare Sector Announced Financial Results and Recognition - Research Report on Alnylam Pharmaceuticals, Opko, Enzymotec, Cambrex, and XOMA 8:00 a.m. Nov. 15, 2013 - PR Newswire
RXi Pharmaceuticals' Valuation Moves From Product To Platform 10:19 a.m. Nov. 12, 2013 - ACCESSWIRE
Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 11, 2013 - BusinessWire
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02) 11:28 p.m. Nov. 10, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Alnylam to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology (ASH) 9:00 a.m. Nov. 7, 2013 - BusinessWire
Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results 4:00 p.m. Nov. 6, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on ALN-AAT, an RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) for the Treatment of AAT Deficiency Liver Disease 2:00 p.m. Nov. 2, 2013 - BusinessWire
Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming Earnings Schedules - Research Report on Illumina, DENTSPLY, Alnylam, Sirona, and Santarus 9:00 a.m. Nov. 1, 2013 - PR Newswire
Alnylam to Webcast Conference Call Discussing Third Quarter 2013 Financial Results 4:00 p.m. Oct. 30, 2013 - BusinessWire
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia A and B 8:00 a.m. Oct. 29, 2013 - BusinessWire
Leading stocks prove their mettle 11:53 a.m. Aug. 22, 2013 - The Trading Deck
Don't fight the tape 10:27 a.m. May 28, 2013 - The Trading Deck
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Synageva director bought shares for trust 1:41 p.m. Jan. 17, 2013 - Insider Monkey
Six stocks to watch for potential up moves 11:14 a.m. Jan. 17, 2013 - The Trading Deck
S&P 500 challenges the 1,440 resistance 9:27 a.m. Sept. 13, 2012 - Michael Ashbaugh
Investing in ‘junk DNA’ 9:28 p.m. Sept. 11, 2012 - Jen Wieczner
Monsanto inks biopesticides deal with Alnylam 8:30 a.m. Aug. 28, 2012 - MarketWatch.com
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 2:35 p.m. July 16, 2012 - MarketWatch
Alnylam soars 31% on drug study 10:19 a.m. July 16, 2012 - Val Brickates Kennedy
Alnylam: Progress with genetic-disorder treatment 6:35 a.m. July 16, 2012 - MarketWatch.com
3 med stocks to get your heart pumping 12:53 p.m. April 5, 2012 - The Trading Deck
Stocks to watch Thursday: GM, Agilent, NetApp 6:51 a.m. Feb. 16, 2012 - MarketWatch
Alnylam climbs 16% on stock offer pricing 2:07 p.m. Feb. 15, 2012 - Val Brickates Kennedy
Stocks to watch Wednesday: Hartford, Aflac, Zynga 6:45 a.m. Feb. 15, 2012 - MarketWatch
Tuesday’s biggest gaining and declining stocks 5:47 p.m. Feb. 14, 2012 - Sue Chang
MGM, Monsanto among Tuesday upgrades 10:54 a.m. Sept. 13, 2011 - Tom Bemis
Vertex, Alnylam gain in drug-stock trading 12:22 p.m. Feb. 23, 2011 - Val Brickates Kennedy
Alnylam shares jump on analyst upgrade 9:55 a.m. Feb. 23, 2011 - Val Brickates Kennedy
Alnylam: Bold Moves Toward A New Class Of Medicine 6:33 p.m. Dec. 11, 2013 - Seeking Alpha
Isis Ally Alnylam - Trying To Understand Its Astounding Valuations 10:06 a.m. Dec. 10, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH 7:59 p.m. Dec. 9, 2013 - benzinga.com
Alnylam's CEO Presents at The 25th Annual Piper Jaffray Healthcare Conference (Transcript) 4:21 p.m. Dec. 4, 2013 - Seeking Alpha
Best Biotech CEO of 2013: Your Vote Counts 8:07 a.m. Dec. 4, 2013 - TheStreet.com
Alnylam Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) 2:01 p.m. Dec. 2, 2013 - Seeking Alpha
Alnylam Earns Milestone Payment - Analyst Blog 5:52 p.m. Nov. 26, 2013 - Zacks.com
Today's Stocks Driving Success For The Drugs Industry 12:04 p.m. Nov. 26, 2013 - TheStreet.com
Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran 6:02 a.m. Nov. 25, 2013 - benzinga.com
Biotech Stock Roundup: Vanda Soars, Sarepta Slumps - Analyst Blog 11:33 a.m. Nov. 20, 2013 - Zacks.com
First Week Of ALNY January 2014 Options Trading 11:55 a.m. Nov. 19, 2013 - TheStreet.com
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American Heart Association Meeting 3:54 p.m. Nov. 17, 2013 - benzinga.com
Alnylam Pharmaceuticals Larger Than S&P 500 Component Teradyne 4:39 p.m. Nov. 15, 2013 - TheStreet.com
Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial 8:26 a.m. Nov. 10, 2013 - benzinga.com
Wider-than-Expected Q3 Loss at Alnylam - Analyst Blog 10:00 a.m. Nov. 7, 2013 - Zacks.com
10-Q: ALNYLAM PHARMACEUTICALS, INC. 8:20 a.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Alnylam Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript 11:43 p.m. Nov. 6, 2013 - Seeking Alpha
3 Potential Game-Changers In The Biotech Industry 4:45 p.m. Nov. 5, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AAT 3:12 p.m. Nov. 2, 2013 - benzinga.com
Pipeline Progress at Alnylam - Analyst Blog 6:05 p.m. Oct. 30, 2013 - Zacks.com
Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR) 8:00 a.m. Today - BusinessWire
Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on Medtronic, Auxilium, Alnylam, Infinity, and Halozyme 8:00 a.m. Dec. 11, 2013 - PR Newswire
Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD) 7:00 p.m. Dec. 9, 2013 - BusinessWire
New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 7:30 p.m. Dec. 8, 2013 - BusinessWire
Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena Biopharma, Amedisys, and Aeterna Zentaris 8:00 a.m. Dec. 3, 2013 - PR Newswire
Alnylam to Webcast Presentation at Upcoming Investor Conferences 4:00 p.m. Nov. 25, 2013 - BusinessWire
Upcoming Webinars, FDA Clearances, Preclinical Data Presentations, Completed Acquisitions and Financial Results - Research Report on Teva, Boston Scientific, Alnylam, Wright Medical, and Onconova 8:00 a.m. Nov. 25, 2013 - PR Newswire
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 25, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting 4:00 p.m. Nov. 17, 2013 - BusinessWire
Healthcare Sector Announced Financial Results and Recognition - Research Report on Alnylam Pharmaceuticals, Opko, Enzymotec, Cambrex, and XOMA 8:00 a.m. Nov. 15, 2013 - PR Newswire
RXi Pharmaceuticals' Valuation Moves From Product To Platform 10:19 a.m. Nov. 12, 2013 - ACCESSWIRE
Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 11, 2013 - BusinessWire
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02) 11:28 p.m. Nov. 10, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Alnylam to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology (ASH) 9:00 a.m. Nov. 7, 2013 - BusinessWire
Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results 4:00 p.m. Nov. 6, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on ALN-AAT, an RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) for the Treatment of AAT Deficiency Liver Disease 2:00 p.m. Nov. 2, 2013 - BusinessWire
Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming Earnings Schedules - Research Report on Illumina, DENTSPLY, Alnylam, Sirona, and Santarus 9:00 a.m. Nov. 1, 2013 - PR Newswire
Alnylam to Webcast Conference Call Discussing Third Quarter 2013 Financial Results 4:00 p.m. Oct. 30, 2013 - BusinessWire
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia A and B 8:00 a.m. Oct. 29, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼